Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

Active, not recruitingOBSERVATIONAL
Enrollment

232

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

May 1, 2026

Conditions
CV2 Autoimmunity
Interventions
OTHER

Description of clinical, immunological and tumor features of patients harboring CV2 Abs

This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.

Trial Locations (1)

69677

Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est, Bron

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT06620913 - Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity | Biotech Hunter | Biotech Hunter